National advisory board on diabetes mellitus: unsolved issues and new opportunities for diabetes treatment
In June 2014, the national experts on diabetes mellitus discussed the opportunities to improve the efficacy and outcomes of diabetes treatment using the strategy of patient-oriented care in diabetes. Insulin degludec (Tresiba?) is a new basal ultra-long-acting insulin analogue with a flat, stable gl...
Saved in:
Main Author: | Gagik Radikovich Galstyan |
---|---|
Format: | article |
Language: | EN RU |
Published: |
Endocrinology Research Centre
2014
|
Subjects: | |
Online Access: | https://doaj.org/article/24b4ef9c9f704b85892f4bf526c0a719 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Data on the first experience of insulin degludec (Tresiba®) treatment for type 2 diabetes in daily clinical practice
by: Lyudmila Alexandrovna Suplotova, et al.
Published: (2015) -
Insulin degludec is a new ultra-long-acting insulin analogue
by: Ivan Ivanovich Dedov, et al.
Published: (2014) -
The first and only combination of basal and prandial insulin analogs degludec and aspart: the position of Russian endocrinologists
by: M. V. Shestakova, et al.
Published: (2021) -
Modern basal insulins: an ongoing story or the start of a new era?
by: Ivan Ivanovich Dedov
Published: (2015) -
Fear of hypoglycaemia in patients with type 1 diabetes
by: Evgenia Mikhailovna Patrakeeva, et al.
Published: (2014)